论文部分内容阅读
目的:分析高胆固醇血症患者服用他汀类调脂药前后血清触珠蛋白(haptoglobin,Hp)水平的变化,探讨其与他汀类药物治疗的关系和临床意义。方法:入组原发性高胆固醇血症患者32例,分别服用洛伐他汀/烟酸缓释片(10 mg/500 mg.d-1)和匹伐他汀(2 mg.d-1),治疗8周后,观察药前、药后血清Hp水平的变化。结果:高胆固醇血症患者分别服用2种他汀类调脂药物后,两组Hp水平均高于治疗前(P<0.05)。其中,服用洛伐他汀/烟酸缓释片的患者,Hp增加了17.87%;服用匹伐他汀的患者,Hp增加了19%。结论:服用他汀药物后,高胆固醇血症患者的血清Hp水平增加。
Objective: To analyze the changes of serum haptoglobin (Hp) levels in patients with hypercholesterolemia before and after taking statins, and to explore its relationship with statin therapy and its clinical significance. Methods: Thirty-two patients with primary hypercholesterolemia were treated with lovastatin / niacin sustained-release tablets (10 mg / 500 mg.d-1) and pitavastatin (2 mg.d-1) After 8 weeks of treatment, the changes of serum Hp level before and after treatment were observed. Results: After taking two statin lipid-lowering drugs in patients with hypercholesterolemia, Hp levels in both groups were significantly higher than before treatment (P <0.05). Among them, patients taking lovastatin / nicotinic acid sustained-release tablets, Hp increased by 17.87%; patients taking pitavastatin, Hp increased by 19%. CONCLUSIONS: Serum Hp levels are elevated in patients with hypercholesterolemia after taking statins.